Abbott Laboratories $ABT Shares Sold by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,076 shares of the healthcare product maker’s stock after selling 206 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Abbott Laboratories were worth $1,778,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC purchased a new position in Abbott Laboratories in the first quarter worth approximately $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories in the first quarter valued at $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.7%

Abbott Laboratories stock opened at $133.63 on Tuesday. The firm has a market capitalization of $232.58 billion, a P/E ratio of 16.75, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock’s fifty day simple moving average is $132.08 and its 200-day simple moving average is $131.44.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent analyst reports. Mizuho upped their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. BTIG Research decreased their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Royal Bank Of Canada lifted their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Wells Fargo & Company decreased their price target on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Finally, Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.39.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.